## 5 Conclusions  
This study has provided a review of the recent progress in the research and practical application of MOFs, mainly Fe-MOFs, with a special emphasis on their potential as catalysts in heterogeneous AOPs. Thus, it has been also shown that Fe-MOF structures can be rationally designed through several synthesis methods and details about these procedures are summarized in Table 4. Based on the extensive literature reviewed, it is also concluded that this great designability of Fe-MOFs allows obtaining catalysts on-demand,  
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline  & & \multicolumn{2}{c}{**Removal**} & \multicolumn{2}{c}{**Reuses (n\({}^{*}\) Cycles/\%)**} \\
**MOF** & **Pollutants** & **AOP** & **(\%\_Degradation/Time (min))** & **Reuses (n\({}^{*}\) Cycles/\%)** & **Reference** \\ \hline
3 \% Fe-MOF/CM & TC & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 100\%/0 min & 4/90\% & [179] \\ g-C3 Nu/NH2-ML-101(Fe) & Acetaminophen & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 94\%/60 min & 10/-88\% & [216] \\ g-C3N4/PDI@NH2-ML-53(Fe) & TC & Photocatalytic/H\({}_{2}\)O\({}_{9}\) & 90\%/60 min & 5/- & [185] \\ g-C3N4/PDI@NH2-ML-53(Fe) & Carbamazepine (CBZ) & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 75\%/150 min & 5/- & [185] \\ g-C3N4/PDI@NH2-ML-53(Fe) & BPA & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 100\%/10 min & 5/- & [185] \\ g-C3N4/PDI@NH2-ML-53(Fe) & 4-NP & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 100\%/30 min & 5/- & [185] \\ g-C3N4/PDI@NH2-ML-53(Fe) & 4-NP & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 100\%/30 min & 5/- & [185] \\ \hline MIL-88A(Fe)/MC & Oxytetracycline (OTC) & Photocatalytic sulfate & 98.2\%/240 min & 30/83.7\% & [187] \\  & & radical & & & \\ MIL-88A(Fe)/MC & TC & Photocactivated sulfate & 98.3\%/240 min & 30/78.8\% & [187] \\  & & radical & & & \\ MIL-88A(Fe)/MC & Chlortetracycline (CTC) & Photocactivated sulfate & 100\%/240 min & 30/88.1\% & [187] \\
6\%ML-88A@BCN & Phenol & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 92.7\%/30 min & 5/93-88\% & [217] \\
6\%ML-88A@BREN & Phenol & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 91.1\%/30 min & 5/92-87\% & [217] \\ Bio-O1R@ML-100(Fe) & Davoycylene & Photocactivated sulfate & 100\%/130 min & 5/100-90\% & [218] \\ BiOBr/ML-53(Fe) & CBZ & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 85\%/100 min & 0 & [219] \\ Fe\({}_{2}\)O\({}_{5}\)-OHII-53(Fe) & Duprofen & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 99\%/60 min & 5/95\% & [220] \\ Fe\({}_{2}\)U-to-Ge & Sulfanter & Photocactivated sulfate & 90\%/300 min & 5/99-95\% & [189] \\  & & radical & & & \\ MIL-101(Fe)/TiO\({}_{2}\) & TC & Photocatalytic/H\({}_{2}\)O\({}_{5}\) & 92.8\%/10 min & 5/93-90\% & [221] \\ PDINH/ML-88A & Chloroquine phosphate & Photocactivated sulfate & 94.6\%/30 min & 5/93.8\% & [188] \\ AF68@MIL-101(Fe) & Diazmon & Photo-Fenton & 100\%/105 min & 4/100-97\% & [222] \\ AF68@MIL-101(Fe) & Atrazine & Photo-Fenton & 81\%/105 min & 4/81-75\% & [222] \\ Cu\({}_{3}\)O/MLF\({}_{2}\)/Ce/Au & Thielacryloid & Photo-Fenton & 82.3\%/30 min & 10/-95\% & [223] \\ Co-Fe PBAs & Levofloxacin & Fenton-like with PMS & 97.6\%/100 min & 5/83.7\% & [164] \\ CUGs/MIL-101(Fe,Cu) & CIP & Fenton-like & 93.5\%/30 min & 4/88.4\% & [24] \\ Fe(PyBDC) & SMX & Fenton-like with PS & 98.7\%/180 min.